Top Markets
Coin of the day
I'rom Group Co., Ltd. I'rom Group Co., Ltd.

I'rom Group Co., Ltd.

2372
株式のランク #17926
I'rom Group Co., Ltd. is a Japanese enterprise specializing in several key... I'rom Group Co., Ltd. is a Japanese enterprise specializing in several key areas: pioneering advanced medical treatments, offering site management organization (SMO) services, acting as a contract research organization (CRO), and providing various forms of medical support. The company spearheads the creation of cutting-edge medical technologies, particularly in regenerative medicine and gene therapy, to combat conditions like obstructive arteriosclerosis, retinitis pigmentosa, and HIV/AIDS. Their innovative contributions include the Sendai virus vector and the CytoTune-iPS kit, designed for generating induced pluripotent stem cells. Furthermore, I'rom assists medical institutions with clinical trial execution and delivers extensive support for the development of novel drugs and medical equipment, with a focus on cancer, rare, and intractable diseases. The company also oversees the establishment and operation of clinic malls. Founded in Tokyo in 1997, it was formerly known as I'Rom Holdings Co., Ltd. until its name change in July 2015.
株価
$18.20
最終同期: 2025-05-09
時価総額
$220.35M
変化(1日)
-5.34%
変化(1年)
0.00%
JP
取引 I'rom Group Co., Ltd. (2372)

カテゴリー

I'rom Group Co., Ltd.(2372)の利益
Dec 2024 時点の利益 TTM: $9.98M
I'rom Group Co., Ltd. の最新の財務報告によると、同社の現在の利益は $9.98M です。2023 年には $25.17M の利益を上げ、これは 2022 年の利益 $21.24M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
I'rom Group Co., Ltd. の利益の推移(2005 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $9.98M -23.16%
2024 $12.99M -48.39%
2023 $25.17M 18.51%
2022 $21.24M 39.44%
2021 $15.23M 45.30%
2020 $10.48M -1.23%
2019 $10.61M -38.18%
2018 $17.17M 595.33%
2017 $2.47M -134.25%
2016 $-7.21M 43.61%
2015 $-5.02M 55.00%
2014 $-3.24M -117.10%
2013 $18.94M -1,247.10%
2012 $-1.65M -227.92%
2011 $1.29M -117.79%
2010 $-7.26M -93.02%
2009 $-104.01M 912.86%
2008 $-10.27M 79.68%
2007 $-5.72M -184.52%
2006 $6.76M -56.10%
2005 $15.40M 0.00%
同業他社の利益